We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Type
- ARTG (87)
- Cancellation by sponsor (27)
- Prescription medicine registration (14)
- Australian Public Assessment Report (AusPAR) (11)
- Prescription medicine evaluation (4)
- Section 14, TGO91 consent (3)
- Prescription medicine decision summary (2)
- Cancellation or suspension (1)
- Designation or determination (1)
Results for
"[search-keyword]"
Sponsor content
150 result(s) found, displaying 1 to 10
-
Australian Public Assessment Report (AusPAR)Onakta (tirbanibulin) was approved for the topical field treatment of actinic keratosis of the face or scalp in adults.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Bulk Influenza Vaccine (Split virion, inactivated) Thiomersal-free.
-
Jul-2024Prescription medicine evaluationActive ingredient: Influenza virus haemagglutinin.
-
Jul-2024Prescription medicine evaluationActive ingredient: Influenza virus haemagglutinin.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ONAKTA tirbanibulin 1% w/w ointment sachet.
-
May-2024Prescription medicine evaluationActive ingredient: Influenza virus haemagglutinin.
-
May-2024Prescription medicine evaluationActive ingredient: Influenza virus haemagglutinin.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Panvax H5N8 pre-pandemic, Pre-pandemic influenza vaccine (split-virion, inactivated) 10 mL multi-dose injection vial.
-
Prescription medicine decision summaryOnakta (tirbanibulin) is indicated for the topical field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis of the face or scalp in adults.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for FLUAD QUAD prefilled syringe(Influenza Surface Antigen,MF59C.1 adjuvanted vaccine).